Skip to main content

Table 1 Disease characteristics of patients

From: Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer

  Number of patients Percent (%)
Sites of extra-osseous disease
   None 64 58.2
   Liver Only 14 12.7
   Brain Only 1 0.9
   Lung Only 3 2.7
   Multiple 11 10.0
   Other 15 13.6
   Unknown 2 1.8
Number of bone lesions
   1 10 9.1
   2–5 40 36.4
   >5 55 50.0
   Unknown 5 4.5
Treatment prior to bisphosphonates
   Nil 33 30.0
   Chemotherapy +/- hormone 31 28.2
   Hormone therapy alone 46 41.8
Hormone therapy prior to bisphosphonates
   1st line 31 28.2
   2nd line 19 17.3
   3rd line 3 2.7
   Not applicable 57 51.8
Median survival from start of bisphosphonates Days (95% CI)
   All subjects 818 (644–911)
   Subjects with bone metastases only 998 (653–1342)
   Subjects with extra-osseous metastases 513 (339–686)
  1. * based on available imaging, either bone scan, skeletal survey, CT or MRI.